Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials.
Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Surana R, et al. Among authors: yap ta. J Gastrointest Cancer. 2023 Dec;54(4):1308-1315. doi: 10.1007/s12029-023-00930-7. Epub 2023 Apr 29. J Gastrointest Cancer. 2023. PMID: 37119430
Untying the gordion knot of targeting MET in cancer.
Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Raghav K, et al. Among authors: yap ta. Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Cancer Treat Rev. 2018. PMID: 29730462 Review.
PARP inhibition - opportunities in pancreatic cancer.
Pant S, Maitra A, Yap TA. Pant S, et al. Among authors: yap ta. Nat Rev Clin Oncol. 2019 Oct;16(10):595-596. doi: 10.1038/s41571-019-0257-6. Nat Rev Clin Oncol. 2019. PMID: 31332344 No abstract available.
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. Yap TA, et al. Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28. Cancer Discov. 2021. PMID: 32988960 Free PMC article.
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.
Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Alhalabi O, et al. Among authors: yap ta. Mol Cancer Res. 2021 Mar;19(3):395-402. doi: 10.1158/1541-7786.MCR-20-0751. Epub 2020 Dec 15. Mol Cancer Res. 2021. PMID: 33323389
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. Hegde A, et al. Among authors: yap ta. Clin Cancer Res. 2021 Jun 1;27(11):3050-3060. doi: 10.1158/1078-0432.CCR-20-4118. Epub 2021 Mar 26. Clin Cancer Res. 2021. PMID: 33771853 Free PMC article. Clinical Trial.
Development of Immunotherapy Combination Strategies in Cancer.
Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Yap TA, et al. Cancer Discov. 2021 Jun;11(6):1368-1397. doi: 10.1158/2159-8290.CD-20-1209. Epub 2021 Apr 2. Cancer Discov. 2021. PMID: 33811048 Free PMC article. Review.
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Yao S, et al. Among authors: yap ta. Sci Rep. 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. Sci Rep. 2022. PMID: 35610322 Free PMC article. Review.
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Mendoza TR, et al. Among authors: yap ta. Sci Rep. 2022 Aug 23;12(1):14367. doi: 10.1038/s41598-022-16588-3. Sci Rep. 2022. PMID: 35999229 Free PMC article. Clinical Trial.
236 results